Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 49Prostatic Neoplasms, Castration-Resistant 3Adenocarcinoma 3Urogenital Neoplasms 2Salivary Gland Neoplasms 2Prostatic Diseases 2Non-metastatic Castration-resistant Prostate Cancer 2Neoplasms 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Male Urogenital Diseases 2Bulbo-Spinal Atrophy, X-Linked 2Biochemically Recurrent Prostate Cancer 2Urogenital Diseases 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Refractory or Relapsed Solid Tumors 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Neoplasms by Site 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1High-Risk Localized Prostate Cancer 1Granulosa cell tumor of the ovary 1Genital Diseases, Male 1Fatigue 1Depression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

olaparib 4Pluvicto 4Abiraterone Acetate 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1cabozantinib 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × darolutamide × 1 year × Clear all
NCT07244341 2026-05-15

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Daiichi Sankyo

Phase 1 Recruiting
60 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡